Injectafer® (ferric carboxymaltose) – New indication
May 31, 2023 - The FDA approved Daiichi Sankyo’s Injectafer (ferric carboxymaltose), for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity.
Download PDF
